Imidazoline receptor agonists for managing hypertension may hold promise for treatment of intracerebral hemorrhage

J. Mahmoudi, A. Majdi, S. Lattanzi, M. Di Napoli, E. M. Bershad, C. M.P. Rodrigues, A. A. Divani

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Intracerebral hemorrhage (ICH), which accounts for 10% of all strokes, leads to higher morbidity and mortality compared with other stroke subtypes. Hypertension has been recognized as a major risk factor for ICH. Current antihypertensive options have not been fully effective for either prevention of ICH or ameliorating its complications. Therefore, attempts should be made to use novel antihypertensive medications for more effective management of blood pressure (BP) in the acute phase of ICH. Imidazoline receptor (IR) agonists can potentially be effective agents for BP control with the adjunctive ability to attenuate post-ICH brain injury. IR agonists render neuroprotective effects including inhibition of inflammatory reactions, apoptotic cell death, excitotoxicity, and brain edema. Given these properties, the present review aims to focus on the application of IR agonists for managing BP in ICH patients.

Original languageEnglish (US)
Pages (from-to)241-251
Number of pages11
JournalCurrent Molecular Medicine
Volume18
Issue number4
DOIs
StatePublished - Jan 1 2018

Keywords

  • Apoptosis
  • Excitotoxicity
  • Hypertension
  • Imidazoline receptors
  • Inflammation
  • Intracerebral haemorrhage

Fingerprint Dive into the research topics of 'Imidazoline receptor agonists for managing hypertension may hold promise for treatment of intracerebral hemorrhage'. Together they form a unique fingerprint.

Cite this